Amit Chaudhary
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Amit Chaudhary has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Neha Jain
Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Noida, India
4 shared publications - Upendra Nagaich
Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Noida, India
3 shared publications - Aruna Sharma
Chitkara University
2 shared publications - Shreya Kaul
Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Noida, India
2 shared publications - Ameya Sharma
Chitkara University School of Pharmacy, Chitkara University, Baddi 174103, Himachal Pradesh, India
1 shared publication - Anchal Sharma
School of Pharmacy, Abhilashi University Chailchowk, India
1 shared publication
Latest Publications
- 12 November 2026
- Published by Springer Nature in Microchimica Acta
- Vol. 193 (12)
Biofilm-responsive nanogels: a closed-loop system for on-demand antimicrobial release for chronic wounds
- 12 November 2026
- Published by Springer Nature in Microchimica Acta
- Vol. 193 (12)
Biofilm-responsive nanogels: a closed-loop system for on-demand antimicrobial release for chronic wounds
- 25 September 2026
- Published by Bentham Science Publishers Ltd. in Recent Patents on Nanotechnology
- Vol. 20, 1-13
Nanogel-Enabled Transdermal Platforms for Targeted Management of Biofilm-Associated Chronic Infections
Introduction/Objective: The problem of biofilm infections is of considerable clinical importance because of the presence of an EPS matrix, metabolic heterogeneity, and antimicrobial tolerance, leading to low penetration of antibiotics and contributing to the failure of therapy and the development of antimicrobial resistance. This review attempts to emphasize the advantages of using nanogel-based transdermal drug delivery for the efficient treatment of biofilm-associated infections. Methods: The review of the relevant literature has been conducted in order to assess the potential of nanogel-based delivery systems, especially as transdermal approaches in the therapy of biofilmassociated infections. Results: Nanogels have unique properties: they are nano-sized, contain high amounts of water, and are polymeric, allowing them to penetrate into biofilms. They can load hydrophilic and lipophilic compounds and allow the co-delivery of antibiotics with agents that disrupt biofilms, such as enzymes and quorum-sensing inhibitors. In transdermal formulations, nanogels can offer controlled drug release, improved penetration and retention in the tissues, and lower systemic exposure. The preclinical results show enhanced biofilm disruption, low minimum biofilm eradication concentration, and faster wound healing. Discussion: Some of the recent developments are hybrid systems that combine nanogels with microneedles or hydrogel patches that can ensure site-specific and controlled drug delivery. Patent developments such as WO2023212124A1, EP4514412A1, and US 11,129,975 further support this fact and reflect the translational potential of these systems. Nonetheless, scalability and stability have emerged as major obstacles to clinical translation. Conclusion: Nanogel-mediated transdermal delivery is one of the most exciting approaches that could be used for treating biofilm infections. Though faced with some issues such as scalability, stability, sterilization, and standardization, development of smart materials and drug delivery systems and personalized medicine could help in translating this approach into clinical use.
- 25 September 2026
- Published by Bentham Science Publishers Ltd. in Recent Patents on Nanotechnology
- Vol. 20, 1-13
Nanogel-Enabled Transdermal Platforms for Targeted Management of Biofilm-Associated Chronic Infections
Introduction/Objective: The problem of biofilm infections is of considerable clinical importance because of the presence of an EPS matrix, metabolic heterogeneity, and antimicrobial tolerance, leading to low penetration of antibiotics and contributing to the failure of therapy and the development of antimicrobial resistance. This review attempts to emphasize the advantages of using nanogel-based transdermal drug delivery for the efficient treatment of biofilm-associated infections. Methods: The review of the relevant literature has been conducted in order to assess the potential of nanogel-based delivery systems, especially as transdermal approaches in the therapy of biofilmassociated infections. Results: Nanogels have unique properties: they are nano-sized, contain high amounts of water, and are polymeric, allowing them to penetrate into biofilms. They can load hydrophilic and lipophilic compounds and allow the co-delivery of antibiotics with agents that disrupt biofilms, such as enzymes and quorum-sensing inhibitors. In transdermal formulations, nanogels can offer controlled drug release, improved penetration and retention in the tissues, and lower systemic exposure. The preclinical results show enhanced biofilm disruption, low minimum biofilm eradication concentration, and faster wound healing. Discussion: Some of the recent developments are hybrid systems that combine nanogels with microneedles or hydrogel patches that can ensure site-specific and controlled drug delivery. Patent developments such as WO2023212124A1, EP4514412A1, and US 11,129,975 further support this fact and reflect the translational potential of these systems. Nonetheless, scalability and stability have emerged as major obstacles to clinical translation. Conclusion: Nanogel-mediated transdermal delivery is one of the most exciting approaches that could be used for treating biofilm infections. Though faced with some issues such as scalability, stability, sterilization, and standardization, development of smart materials and drug delivery systems and personalized medicine could help in translating this approach into clinical use.
- 10 June 2026
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 23 (8) , 1-25
Bioconjugates for breast cancer theranostics: improving target selectivity and treatment efficacy
1. Breast cancer is one of the most frequently diagnosed cancers worldwide, and it is a markedly heterogeneous disorder. Heterogeneity in breast cancer is seen at various levels, such as interpatie...
- 10 June 2026
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 23 (8) , 1-25
Bioconjugates for breast cancer theranostics: improving target selectivity and treatment efficacy
1. Breast cancer is one of the most frequently diagnosed cancers worldwide, and it is a markedly heterogeneous disorder. Heterogeneity in breast cancer is seen at various levels, such as interpatie...
- Open Access
- 31 August 2025
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 41 (4) , 1188-1193
Exploration of Skin Permeability Possibility of Cubogels for Keratosis-like Skin Conditions
Actinic keratosis (AK) is a chronic skin condition caused primarily by prolonged sun exposure, leading to the development of uneven, scaly patches on sun-exposed areas like the face, chest, and neck. Traditional treatments often encounter challenges such as poor skin permeability and formulation stability. This study investigates the potential of cubosomal hydrogels for enhancing the treatment of AK, focusing on their permeability, and effectiveness. Cubosomes, a type of liquid crystalline nanoparticle, are known for their controlled release and improved skin penetration capabilities. We formulated tretinoin-loaded cubosomes and incorporated them into carbopol-based hydrogels, referred to as cubogels, to address issues related to stability and ease of application. The formulation of tretinoin-loaded cubosomes was optimized, resulting in particles with a size of 69.5 nm, a polydispersity index of 0.312, and an entrapment efficiency of 82.13%. These cubosomes were then dispersed in hydrogels made with varying concentrations of Carbopol 940 (0.5%, 1.0%, and 1.5%). The cubogels were evaluated for physical properties, including appearance, pH, viscosity, spreadability, and drug content uniformity. The hydrogels exhibited good homogeneity and appropriate pH levels, with CG2 (1.0% Carbopol) showing the best spreadability and drug content uniformity. Ex-vivo studies using goat ear pinna demonstrated that CG2 provided the highest steady-state flux and permeability coefficient, indicating superior skin penetration. The cumulative drug permeation over 24 hours was also higher for CG2 compared to the other formulations. In conclusion, the incorporation of cubosomes into hydrogels significantly enhances the stability and skin permeability of tretinoin, offering a promising approach for the treatment of actinic keratosis. Future studies should focus on clinical evaluation to confirm these findings and further optimize the formulation for broader therapeutic applications.
- 31 August 2025
- Published by Oriental Scientific Publishing Company in Oriental Journal of Chemistry
- Vol. 41 (4) , 1188-1193
Open AccessExploration of Skin Permeability Possibility of Cubogels for Keratosis-like Skin Conditions
Actinic keratosis (AK) is a chronic skin condition caused primarily by prolonged sun exposure, leading to the development of uneven, scaly patches on sun-exposed areas like the face, chest, and neck. Traditional treatments often encounter challenges such as poor skin permeability and formulation stability. This study investigates the potential of cubosomal hydrogels for enhancing the treatment of AK, focusing on their permeability, and effectiveness. Cubosomes, a type of liquid crystalline nanoparticle, are known for their controlled release and improved skin penetration capabilities. We formulated tretinoin-loaded cubosomes and incorporated them into carbopol-based hydrogels, referred to as cubogels, to address issues related to stability and ease of application. The formulation of tretinoin-loaded cubosomes was optimized, resulting in particles with a size of 69.5 nm, a polydispersity index of 0.312, and an entrapment efficiency of 82.13%. These cubosomes were then dispersed in hydrogels made with varying concentrations of Carbopol 940 (0.5%, 1.0%, and 1.5%). The cubogels were evaluated for physical properties, including appearance, pH, viscosity, spreadability, and drug content uniformity. The hydrogels exhibited good homogeneity and appropriate pH levels, with CG2 (1.0% Carbopol) showing the best spreadability and drug content uniformity. Ex-vivo studies using goat ear pinna demonstrated that CG2 provided the highest steady-state flux and permeability coefficient, indicating superior skin penetration. The cumulative drug permeation over 24 hours was also higher for CG2 compared to the other formulations. In conclusion, the incorporation of cubosomes into hydrogels significantly enhances the stability and skin permeability of tretinoin, offering a promising approach for the treatment of actinic keratosis. Future studies should focus on clinical evaluation to confirm these findings and further optimize the formulation for broader therapeutic applications.
- Open Access
- 28 January 2022
- Published by Sciencedomain International in Journal of Pharmaceutical Research International
- p. 39-44
RP HPLC Method Development for Simultaneous Estimation of Etoricoxib and Thiocolchicoside
A simple, specific and accurate reverse phase high performance liquid chromatography (RP-HPLC) method was developed and validated for simultaneous estimation of Etoricoxib and Thiocolchicoside in bulk and solid dosage form. Separation was achieved by Zorbax C-18 analytical column having dimension (250mm * 4.6 mm i.d 5.0 µm) using methanol and water (60:40) as mobile phase and flow rate was 0.7ml/min. The detection was carried out at 283 nm wavelength using UV detector. The total chromatographic sample time per analysis was about 14.0 minutes with thiocolchicoside eluted at retention time 3.523 min and etoricoxib eluted at retention time 9.627 min. The method was validated for accuracy, precision, specificity, rapid, reliable and reproducible. LOD and LOQ value for etoricoxib and thiocolchicoside were found to be 0.332, 0.996 ppm and 0976, 0.928 ppm respectively. Regression Equation for Etoricoxib was y = 0.006x + 0.149 and regression equation for thiocolchicoside was Y = 0.030x + 0.086. As the run time was increased the retention time was decreased, so the method is simple and economical and can be adopted by regular quality control in industries and also in research laboratories.
- 28 January 2022
- Published by Sciencedomain International in Journal of Pharmaceutical Research International
- p. 39-44
Open AccessRP HPLC Method Development for Simultaneous Estimation of Etoricoxib and Thiocolchicoside
A simple, specific and accurate reverse phase high performance liquid chromatography (RP-HPLC) method was developed and validated for simultaneous estimation of Etoricoxib and Thiocolchicoside in bulk and solid dosage form. Separation was achieved by Zorbax C-18 analytical column having dimension (250mm * 4.6 mm i.d 5.0 µm) using methanol and water (60:40) as mobile phase and flow rate was 0.7ml/min. The detection was carried out at 283 nm wavelength using UV detector. The total chromatographic sample time per analysis was about 14.0 minutes with thiocolchicoside eluted at retention time 3.523 min and etoricoxib eluted at retention time 9.627 min. The method was validated for accuracy, precision, specificity, rapid, reliable and reproducible. LOD and LOQ value for etoricoxib and thiocolchicoside were found to be 0.332, 0.996 ppm and 0976, 0.928 ppm respectively. Regression Equation for Etoricoxib was y = 0.006x + 0.149 and regression equation for thiocolchicoside was Y = 0.030x + 0.086. As the run time was increased the retention time was decreased, so the method is simple and economical and can be adopted by regular quality control in industries and also in research laboratories.